‘Incredibly big change’ in treatment of deadly skin cancer, new data show
June 4, 2018
| by Susan Keown / Fred Hutch News Service
Immunotherapy drugs have transformed the treatment of a deadly skin cancer, Merkel cell carcinoma. New trial results show these drugs help many patients survive much longer than would otherwise be possible.
Immune-boosting therapy shows promise for advanced Merkel cell carcinoma
Oct. 6, 2015
| By Dr. Rachel Tompa / Fred Hutch News Service
Skin cancer researcher Dr. Paul Nghiem is leading a clinical trial testing the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Early results from the trial are showing great promise for these patients.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.